全文获取类型
收费全文 | 67693篇 |
免费 | 4567篇 |
国内免费 | 258篇 |
专业分类
耳鼻咽喉 | 806篇 |
儿科学 | 1706篇 |
妇产科学 | 1328篇 |
基础医学 | 8658篇 |
口腔科学 | 1098篇 |
临床医学 | 6492篇 |
内科学 | 14220篇 |
皮肤病学 | 925篇 |
神经病学 | 6473篇 |
特种医学 | 2148篇 |
外国民族医学 | 4篇 |
外科学 | 10968篇 |
综合类 | 962篇 |
现状与发展 | 1篇 |
一般理论 | 80篇 |
预防医学 | 5778篇 |
眼科学 | 1418篇 |
药学 | 4407篇 |
中国医学 | 87篇 |
肿瘤学 | 4959篇 |
出版年
2023年 | 276篇 |
2022年 | 535篇 |
2021年 | 1221篇 |
2020年 | 662篇 |
2019年 | 1095篇 |
2018年 | 1348篇 |
2017年 | 944篇 |
2016年 | 1073篇 |
2015年 | 1211篇 |
2014年 | 1922篇 |
2013年 | 2828篇 |
2012年 | 4139篇 |
2011年 | 4463篇 |
2010年 | 2472篇 |
2009年 | 2339篇 |
2008年 | 4041篇 |
2007年 | 4263篇 |
2006年 | 4196篇 |
2005年 | 4287篇 |
2004年 | 4219篇 |
2003年 | 3834篇 |
2002年 | 3779篇 |
2001年 | 689篇 |
2000年 | 541篇 |
1999年 | 728篇 |
1998年 | 843篇 |
1997年 | 714篇 |
1996年 | 641篇 |
1995年 | 600篇 |
1994年 | 553篇 |
1993年 | 512篇 |
1992年 | 496篇 |
1991年 | 506篇 |
1990年 | 409篇 |
1989年 | 434篇 |
1988年 | 405篇 |
1987年 | 382篇 |
1986年 | 365篇 |
1985年 | 377篇 |
1984年 | 554篇 |
1983年 | 470篇 |
1982年 | 596篇 |
1981年 | 564篇 |
1980年 | 548篇 |
1979年 | 300篇 |
1978年 | 339篇 |
1977年 | 328篇 |
1976年 | 264篇 |
1975年 | 281篇 |
1974年 | 271篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
Internal eye wall resection in the management of uveal melanoma 总被引:3,自引:0,他引:3
G A Peyman H Charles 《Canadian journal of ophthalmology. Journal canadien d'ophtalmologie》1988,23(5):218-223
Twenty patients with presumed uveal melanoma underwent internal eye wall resection. It was the primary procedure in 13 patients who had tumours within 2 disc diameters of the optic nerve head and was combined with external resection in the remainder. Malignant melanoma was confirmed histologically in 15 patients; the diagnosis was a benign tumour in the other 5. The length of follow-up ranged from 2 to 37 (mean 19) months. In all cases the retina was completely attached at the time of last examination. The visual acuity ranged from 20/40 to hand movements; nine patients had an acuity of 20/400 or better. At the time of writing no metastatic disease or local recurrence had developed in any of the 15 patients in whom malignant melanoma was diagnosed. 相似文献
12.
Abraham Nudelman Yitschak Binnes Naomi Shmueli-Broide Yael Odessa J. Paul Hieble Anthony C. Sulpizio 《Archiv der Pharmazie》1996,329(3):125-132
Vinylogous (Groups III and V ) and acetylenologous (Group IV ) analogs of the classical β-adrenergic agents — stimulants and blockers — were prepared in order to evaluate the effect of degree of saturation, position of unsaturation and rigidity of the chain linking the aromatic ring and the amino containing functional group on biological activity. Derivatives from Group III , which represent 4-aryl-3-butenyl-2-ol-amine analogs of Group II , retained β1-adrenoceptor antagonist activity albeit substantially less potent (50–200-fold) than that possessed by their aryloxy counterparts. Consistent with the SAR for Group II compounds, substitution at position 2 of the aromatic ring yielded the most potent antagonists ( 5a, 5d, 5g ), with KB's ranging from 73–93 nM while 3,4-dichloro substitution ( 5e ) markedly reduced antagonist potency (KB = 2,400 nM). Agonist activity was also noted for 5b and 5d , suggesting that these compounds may be best classified as partial agonists. Representatives from Groups IV and V were inactive as antagonists at the β1-adrenoceptor confirming the importance of the spatial relationship between the hydroxyl and the amino nitrogen. 相似文献
13.
14.
15.
16.
17.
Phase I study of high-dose cytosine arabinoside and etoposide in patients with advanced malignancies
Bayard L. Powell Hyman B. Muss Robert L. Capizzi Mary E. Caponera Douglas R. White Patricia J. Zekan James N. Atkins Don V. Jackson Jr. Frederick Richards II John B. Craig Julia M. Cruz Charles L. Spurr 《Cancer chemotherapy and pharmacology》1987,19(3):250-252
Summary Cytosine arabinsodie (ara-C) and etoposide (VP-16) display synergy in the laboratory. Twenty-six patients participated in a phase I study of high-dose ara-C in combination with VP-16. The dose of VP-16 was held constant at 50 mg/m2 as an intermittent infusion over 33 h; escalating doses of ara-C were given as infusions during hours 9–12 and 21–24. Myelosuppression was the dose-limiting toxicity and occurred with doses considerably less than those expected from studies of the two drugs as single agents. The suggested initial doses for phase II trials with this schedule are 750 mg/m2×2 doses of ara-C and 50 mg/m2 of VP-16. Nonhematologic toxicity was minimal; therefore, further dose escalation is feasible in patients in whom myelosuppression is acceptable.Supported in part by grants from the National Cancer Institute (CA-12197 and CA-09422) and the American Cancer Society CF-85-182 相似文献
19.
20.
Joseph F Malouf Manfredi Ballo Heidi M Connolly David O Hodge Regina M Herges Charles J Mullany Fletcher A Miller 《Journal of the American Society of Echocardiography》2005,18(3):252-256
The purpose of this study was to provide, in a large number of patients, comprehensive Doppler echocardiographic assessment of normal St Jude Medical mitral valve prosthesis function using Doppler-derived hemodynamic variables, including the mitral valve prosthesis-to-left ventricular outflow tract time-velocity integral ratio and prosthesis performance index. The pressure half-time was less than 130 milliseconds in all patients, and all but one patient had either a peak early mitral diastolic velocity of 2 m/s or less or a mitral valve prosthesis-to-left ventricular outflow tract time-velocity integral ratio of less than 2.2. There was a significant (P < .001) negative correlation between the prosthesis performance index and prosthesis size. This negative correlation suggests that there is more efficient use of the in vitro geometric orifice area with smaller prostheses. 相似文献